In partnership with Reformulary Group, Aon is now offering employers a proprietary formulary solution, The Reformulary. The Reformulary is an evidence-based list of covered pharmaceuticals that allows employers to better control their drug-plan costs to ensure plan sustainability.
Benefits of The Reformulary include:
Reformulary Group also provides advanced analytical tools, such as the Drug Early Warning (DEW) System, to healthcare stakeholders. This sophisticated predictive modelling tool monitors and evaluates new specialty drugs entering the Canadian market. Using clinical algorithms, it evaluates existing medical conditions and predicts the expected impact of new drugs on a drug plan, or group of drug plans. The DEW System is a proprietary risk management tool that is available to insurance carriers, third-party administrators, consultants and employers.